Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$21.15
--
Market closed
$21.15
--
Day’s Range― - ―
52-Week Range$14.19 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.87M
Market Cap
$4.80B
Enterprise Value$4.66B
Total Cash (Recent Filing)$823.46M
Total Debt (Recent Filing)$430.96M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 18, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding282,680,700
10 Day Avg. Volume3,331,204
30 Day Avg. Volume2,868,486
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue5.13
Enterprise Value/Gross Profit7.47
Enterprise Value/Ebitda41.83
Forecast
1Y Price Target
$27.50Price Target Upside30.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.13
Revenue Forecast (FY)$1.00B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Margin ExpansionSustained double‑digit volume and ASP growth drove a sharp revenue inflection and ~1,800bp gross margin lift to 65%. That mix-driven margin expansion indicates pricing power and operating leverage in core molecular profiling, supporting durable unit economics as volumes scale.
Consistent Positive Cash Generation And EBITDAConsecutive quarters of positive adjusted EBITDA and free cash flow signal an operational shift from prior years of negative cash conversion. Reliable cash generation provides funding for growth initiatives, reduces financing reliance and underpins sustainable investment in products and commercialization.
Large Proprietary Clinicogenomic Dataset And Commercial FootprintA >1M case dataset and deep provider integrations create high switching costs and a defensible moat for pharma partnerships, AI interpretation products, and diagnostics adoption. Network effects and dataset scale support recurring partnerships and long‑term commercial differentiation.
Bears Say
Historic Multi-year Net Losses And Volatile EquityMulti-year heavy losses and a volatile balance sheet reduce confidence in durability: while 2025 shows improvement, historical negative equity and poor ROE reflect inconsistent capital structure and raise the risk that setbacks could require dilutive financing or constrain strategic flexibility.
Ongoing Reimbursement And Market RiskPayer decisions and PAMA/regulatory outcomes can structurally compress ASPs and volumes for diagnostic testing. Even with CDLT coding and submitted PAMA data, sustained payer pressure would erode unit economics and long‑term revenue visibility for clinical and blood‑based assays.
Execution/phasing Risk From Sales Realignment And Higher CapExRapid territory expansion, hiring and large near‑term CapEx create phasing risk: slower rep ramp or delayed product commercialization could pressure volumes and cash flow. Elevated investment cadence may weigh margins until new hires and launches scale predictably.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $4.80B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 37 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.024 by $0.024.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.01.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,680,700 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, beating expectations of -$0.024. Following the earnings report the stock price went down -18.599%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (30.02% Upside)
$27.50 (30.02% Upside)
Blogger Sentiment
Bullish
CAI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 349.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $501.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.17%
12-Months-Change
Fundamentals
Return on Equity
6.47%
Trailing 12-Months
Asset Growth
298.65%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial and financial momentum: substantial revenue and ASP growth, materially improved gross margins, positive adjusted EBITDA and free cash flow, meaningful balance sheet strength, multiple product launches, and encouraging MCED validation data. Headwinds are predominantly timing and phasing related—sales realignment effects on completed cases, short-term Pharma revenue cadence, and elevated near-term investment and CapEx ahead of new product launches. Reimbursement dynamics remain a watch item despite management's confident position. Overall, the positive operational and financial progress and strategic initiatives outweigh the timing and investment-related challenges.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$27.50
▲(30.02% Upside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
48.82% Insiders
16.19% Mutual Funds
0.01% Other Institutional Investors
29.62% Public Companies and
Individual Investors